MK-7762
/ Merck (MSD), Bill & Melinda Gates Foundation
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
October 31, 2025
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09
(clinicaltrials.gov)
- P1 | N=36 | Active, not recruiting | Sponsor: Gates Medical Research Institute | Recruiting ➔ Active, not recruiting
Enrollment closed
October 07, 2025
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Gates Medical Research Institute | Not yet recruiting ➔ Recruiting
Enrollment open
August 01, 2025
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09
(clinicaltrials.gov)
- P1 | N=36 | Not yet recruiting | Sponsor: Gates Medical Research Institute
New P1 trial
July 26, 2024
Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=119 | Completed | Sponsor: Bill & Melinda Gates Medical Research Institute | Recruiting ➔ Completed | Trial completion date: Oct 2024 ➔ Mar 2024 | Trial primary completion date: Oct 2024 ➔ Mar 2024
Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
May 22, 2024
Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=96 | Recruiting | Sponsor: Bill & Melinda Gates Medical Research Institute | Trial completion date: Apr 2024 ➔ Oct 2024
Trial completion date • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
April 21, 2023
Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=96 | Recruiting | Sponsor: Bill & Melinda Gates Medical Research Institute
New P1 trial • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
1 to 6
Of
6
Go to page
1